Resources

Standard outcomes data often limits orthopedic research to broad insights, such as overall success rates, average recovery times, or general complication rates. With Truveta, orthopedic researchers can access device-level insights and patient-reported outcomes from the most complete, timely, and clean regulatory-grade EHR data available.

Understanding the link between maternal health and child outcomes is crucial for advancing both maternal and pediatric care. Truveta’s dataset includes daily updated data from over 1 million mother-child pairs, providing critical insights into how maternal health, behaviors, and exposures influence child outcomes.

Psoriasis is chronic, systemic disease that affects over 8 million people in the United States. Truveta’s complete, timely and clean EHR data includes a psoriasis patient population with over 4.3 million relevant notes. This briefing highlights the possibilities for psoriasis research with robust EHR data.

The FDA supports using real-world evidence for regulatory decision-making but stipulates that the underlying data must be fit for purpose. This briefing highlights Truveta’s approach to ensuring high-quality, fit-for-purpose EHR data and streamlining real-world evidence submissions to regulatory authorities.

De-identified medical images are often hard to find and detached from clinical context, hindering research efforts. Truveta provides access to more than 85 million medical imaging studies integrated with complete EHR data. This briefing provides insight into the images available and how they’re advancing research.

Despite promising clinical data for novel pulmonary embolism therapies, there are no randomized prospective studies comparing them and guidelines have not been updated to reflect real-world safety data. This case study showcases findings from a peer-reviewed study using Truveta Data to compare the safety of devices from Boston Scientific and Inari Medical.

Clinical care affects only 10-20% of modifiable health factors, while 80-90% are influenced by behaviors, socioeconomic factors, and the environment. This briefing highlights how integrating social drivers of health (SDOH) data into real-world data analyses offers precise insights on unmet needs, healthcare disparities, and therapy performance.

Echocardiograms contain crucial clinical observations relevant for cardiovascular research, but obtaining these measures at scale for real-world data analysis has been a longstanding challenge. This briefing highlights how Truveta is normalizing and extracting echo observations at scale for research, and outlines data availability for specific measures.

GLP-1s, originally created to treat diabetes, have been found to suppress appetites and induce substantial weight loss in many patients. Extensive media coverage and celebrity endorsements have created overwhelming demand for these drugs, but little is known about real-world use. This briefing highlights findings from an analysis of first-time GLP-1 prescribing trends.

Peripheral Artery Disease (PAD) is a common disease that causes the narrowing of the arteries in the extremities. As part of PAD Awareness month, Truveta Research investigated disparities in the frequency of common procedures used to treat PAD, known as endovascular (or minimally invasive) revascularization, and the associated outcomes.

Learn why researchers are betting on EHR data as the future of real-world evidence generation and what to look for when evaluating the quality of a real-world dataset.

Speakers from Truveta, Reprieve Cardiovascular, The Permanente Medical Group, and Stanford Cardiovascular Medicine discuss how Truveta Data is being used to drive product innovation for acute heart failure.

Hear from experts at UCB and Truveta as they demonstrate the power of Truveta’s AI-driven extraction of critical information from free text clinical notes to further research at UCB.